Respiratory COPY Flashcards

1
Q

Berlin Criteria

A

For ARDS
- Acute onset
- Respiratory failure not primarily due to hydrostatic oedema
- Bilateral opacities on lung radiograph
- paO2:FiO2 < 300

Management
- Prone nursing
- Low tidal volume ventilation @ 6ml/kg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Home NIV indications in MND

A

VC < 50%
SNIP < 30cm H20
Low max insp pressure (MIP) - diaphragm and inspiratory muscles
Low max exp pressure (MEP) - abdominal and expiratory muscles

Imp in QOL and survival if commenced before bulbar dysfunction but prophylactic NIV before above indications worsens prognosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Predictors of NIV failure

A

Acidosis < 7.25
Marked onset new hyperaemia
Respiratory distress signs with RR > 25
Non-pulmonary organ failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Samters Triad

A

Asthma
Aspirin intolerance
Nasal Polyps

Rx with Leukotriene antagonists

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Allergic Bronchopulmonary Aspergillus

A

Found in the soil, dust, water, vegetation (like dead leaves or compost piles),
- Chronic asthma with brown mucus plugs
- Recurrent pulmonary infiltrates
- Very high total IgE > 1000
- Positive skin test to aspergillus antigens
Rx with steroids, Mepolizumab (anti-IL5) and anti-fungals (Itraconazole)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Eosinophilic granulomatosis with polyangitis (EGPA)

A
  • Churgg Strauss Vasculitis with granulomas
  • Tissue and skin eosinophilia
  • Asthma
  • Cardiac involvement common
  • Renal involvement rare
  • 40% pANCA positive
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Asthma Diagnosis

A

FEV1/FVC < normal
Reversibility > 12% or 200ml

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Anti-IgE Immunotherapy

A

Omalizumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Step 1 Asthma Management

A

PRN low dose ICS + Formoterol

+/- PRN SABA every-time ICS is used

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Step 2 Asthma Management

A

Commence controller if using reliever > 3 times/week;
Daily low dose ICS

Reliever;
PRN low dose ICS + formetarol +/- SABA

+/-
PRN LTRA when SABA taken

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Step 3 Asthma Management

A

Controller;
Daily low dose ICS + LABA
or
Daily low dose ICS + LTRA
or
Daily medium dose ICS alone

Reliever;
PRN Low dose ICS + formetarol

+/-
PRN SABA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Step 4 Asthma Management

A

Controller;
Medium dose ICS + LABA
or
High dose ICS alone +/- Tiotropium

Reliever;
PRN Low dose ICS + formetarol

+/-
PRN SABA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Step 5 Asthma Management

A

Controller
High dose ICS + LABA

plus
Omalizumab

Reliever;
PRN Low dose ICS + formetarol

+/-
PRN SABA
PRN PO corticosteroids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Definition well-controlled Asthma

A

day symptoms < 2 x weekly
night symptoms < 2 x monthly
Over lasy 4 week period

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Mepolizumab & Benralizumab MOA

A

Binds IL-5 receptor for treatment of eosinophilic asthma. Effective in those with eosinophil levels > 150 regardless of IgE Level

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Dupilumab MOA

A

Binds IL4 & IL13 receptor for Asthma and severe eczema

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Alpha-1 anti-trypsin

A

Basilar pan-acinar emphysema
Associated with;
- hepatic cirrhosis and HCC
- panniculitis of skin
- Bronchiectasis
- Check alpha-1 antitrypsin level if COPD < 45 yrs old, FHx or absence of RF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

mMRC dyspnoea score

A

Dyspnea only with strenuous exercise = 0

Dyspnea when hurrying or walking up a slight hill = 1

Walks slower than people of the same age because of dyspnea or has to stop for breath when walking at own pace = 2

Stops for breath after walking 100 yards (91 m) or after a few minutes = 3

Too dyspneic to leave house or breathless when dressing = 4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

GOLD classification

A

A - < 1 exac/year, mMRC 0-1, CAT < 10
B - < 1 exac/year, mMRC > 2 , CAT > 10
C - > 2 exac/year, mMRC 0-1, CAT < 10
D - > 2 exac/year including hospitilisation, mMRC > 2, CAT > 10

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Youngs Syndrome

A

Bronchiectasis, chronic sinusitis and Azospermia due functional blockage of the sperm in the caput epididymis, which is usually enlarged and palpable in the scrotum. Can occur later in life

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Pseudomonas strains with worse outcomes

A

AUST-01 in Melbourne
AUST- 02 in Brisbane

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Smoking related ILD

A
  • Respiratory bronchiolitis associated with ILD
  • Desquamating interstitial pneumonia
  • Pulmonary Langerhans cell histocytosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Lymphangioleiomyomatosis

A
  • Women 30-40
  • Spontaneous PTX
  • Chylous effusions
  • CT showing cystic disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Idiopathic interstitial pneumonias

A
  1. Idiopathic pulmonary fibrosis
  2. Non-specific interstitial pneumonia
  3. Acute interstitial pneumonia
  4. Crypotogenic organising pneumonia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Empyema diagnosis

A

pH < 7.2
Gram stain +
Glucose < 3.3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Rapid Score

A

For pleural effusion
- Renal - Urea > 8
- Age > 70
- Purulent
- Infection - HAP
- dietary factors - Albumin < 27

High risk for poor outcome with pleural effusion

27
Q

LENT Score

A

Predicts survival with malignant pleural effusions;

LDH
ECOG
Neutrophil:Lymphocyte ration
Tumour type

28
Q

Riociguat

A

Dual mode of action, directly stimulating soluble cyclic guanosine monophosphate (cGMP) independently of nitric oxide, and increasing the sensitivity of cGMP to nitric oxide.

29
Q

Apnoea-Hypopnoea Scale

A

Number of apnoeas or hypopnea per hour

Normal < 5
Mild 5 - 14 (treat only if symptomatic)
Moderate 15-30 (treat regardless)
Severe 30 +

30
Q

Kartegener Syndrome

A
  • Associated with DNAI1, DNAH5
  • Situs invertus
  • Chronic sinusitis
  • Bronchiectasis
  • Infertility (male and female)
  • Variable lung function and course - not diagnostic
31
Q

CODEX score

A

Prediction of outcome 3-12 months after hospital admission for COPD

Comorbidities
Obstruction
Dyspnoea
Exacerbations [reviously

32
Q

Lofgren syndrome

A
  • Sarcoidosis
  • Hilar adenopathy
  • Migratory polyarthritis
  • Erythema Nodosum

Associated with a good prognosis,with >90% of patients experiencing disease resolution within 2 years.

33
Q

Treatments NSCLC

A

ANTI - PDL (Durvalumab), ANTI-PD1 (Pembrolizumab, Nivolumab), TYROSINE KINASE inhibit against EGFR, ALK, ROS1

Higher likelihood to TK inhibitors if Asian, female, never-smoker, adenocarcinoma

34
Q

KCO

A

KCO = DLCO (diffusion capacity at one alveolar unit)/VA (accessible alveolar volume)

Low DLCO but high KCO
- Kyphoscoliosis
- Lobectomy
- Severe pleural disease
- diaphragmatic paralysis

35
Q

Causes high DLCO

A

SAMPPLE
- Severe obesity
- Asthma
- Mild LVF
- Polycythaemia
- Pulmonary haemorrhage
- L to R) intracardiac shunting
- Exercise - associated with increased CO

36
Q

REM Sleep disorders

A

Narcolepsy is the disruption of wakefulness into REM (HLA DQB1 0602)

REM behaviour disorder; disruption of REM into wakefulness -> male predominance

37
Q

Staging NSCLC

A

Early - Stage 1-3a (surgical resection)
- Stage 1; < 3cm < 2 nodes
- Stage 2; < 5cm < 2 nodes
- Stage 3a; > 5cm < 1 node

Late - Stage 3b - 4
- Stage 3b; > 5cm > 2 nodes
- Stage 4 any contralateral node or dissemination

38
Q

Aspergillus

A

Associated with bronchopulmonary allergic aspergillus
From compost, soil, dust decaying material
High IgE > 1000, eosinophilia
Positive skin test
Galactomannan (constituent of the aspergilus cell wall) used to Dx invasive aspergillus commonly on immunocompromised patients
Rx with steroids and anti-fungals

39
Q

Small cell Lung Ca

A
  • Strong association with smoking
  • Common mets to brain requires prophylactic whole brain radiation
  • Staging; Local - ipsilateral and single radiation site, Extensive - contralateral, metastatic or outside single radiation field
  • Rx with platinum based CTX (cisplatin + etoposide), radiation plus prophylactic whole brain radiation
  • Paraneoplastic syndromes
40
Q

Cystic Fibrosis Gene Variants

A

Defects in gene on Chromosome 7 associated with CFTR ( Cystic fibrosis transmembrane conductance regulator)

  • Delta 508 - most common - trafficking defect associated with pancreatic exocrine insufficiency and lung disease
  • G551D - defective channel regulation, gate is produced but does not function
  • G542X - Non-functional gate
  • R117H
41
Q

CFTR modulators

A
  • Ivacaftor; opens channel
  • Tezacaftor; moves channel to surface
  • Elexacaftor

G551D - Ivacaftor
homozygous delta508 - Ivacaftor + Tevocaftor
heterozygous delta508 - Ivacaftor + Tevocaftor + Elexacaftor

42
Q

Indications for lung transplant in CF

A

FEV1 < 35% predicted with rapid rate of decline
Increase frequency exacerbations
pO2 < 60mmHg
PCO2 > 50mmHg
Clinical organism resistance
Impaired QOL

43
Q

Haemodynamics in pulmonary hypertension

A

Where pulmonary wedge pressure = left atrial pressure

44
Q

A-a gradient

A

Diffusion of air into alveolar = Age/4 + 4
Normal = hypoxia associated with hypoventilation, not lung disease
Abnormal = hypoxia associated with lung disease

45
Q

Vital Capacity

A

Tidal volume + inspiratory reserve + expiratory reserve

46
Q

Genes type 1 PAH

A
  • BMPR2
  • ALK1

Female predominance

47
Q

Anti fibrotics

A

Pirfenidone; acts at TGF-beta to reduce fibroblast proliferation, SI of photosensitive rash ** improves survival but not dyspnoea scores **

Nintedanib; Inhibits multiple tyrosine kinases (PDGF, VEGF, FGF), SI of diarrhoea

For treatment patient must have VC > 50%, DLCO > 30%

48
Q

R) shift O2 dissassociation curve

A

CADET shift right!
CO2
Acidosis
DPG (2,3)
Exercise
Temperature increase

49
Q

Strains Pseudomonas with worse outcomes

A

AUST-01 in Melbourne
AUST- 02 in Brisbane

50
Q

Rx with no evidence in Bronchiectasis

A

Tiotropium and Steroids

51
Q

Indications for NIV in MND

A
  • VC < 50%
  • SNIP < 30cm H20
  • Low max insp pressure (MIP) - diaphragm and inspiratory muscles
  • Low max exp pressure (MEP) - abdominal and expiratory muscles

Imp in QOL if commenced before bulbar dysfunction but prophylactic NIV before above indications worsens prognosis

52
Q

Metacholine test

A

Repeated measurements of FEV1
If falls < 20% - considered positive

53
Q

Exhaled NO in Asthma

A

> 50ppb exhaled NO indicates steroid responsiveness in allergic asthma

54
Q

Biologicals used in Asthma

A

Omalizumab - binds IgE for treatment of allergic asthma

Mepolizumab- binds IL-5; for treatment of eosinophilic asthma. Effective in those with eosinophil levels > 150 regardless of IgE Level

Benralizumab - IL-5 receptor

Dupilumab - Binds IL4 & IL13 receptor for Asthma and severe eczema

55
Q

Eosinophilic granulomatosis polyangitis

A
  • Small vessel vasculitis
  • Asthma
  • Tissue & blood eosinophilia
  • Rhinosinusitis
  • Granulomatous lung lesions
  • Cardiac disease accounts for 50% of deaths
  • Rarely renal involvement
56
Q

MOA erythromycin

A

Bind the 50s/30s ribosomal complex on RNA to stop protein transcription in susceptible bacteria

Can increase risk of non-Tb mycobacterium

57
Q

“radiating recall” pneumonitis

A

Exposure to etoposide, gemcitabine, paclitaxel and pemitrexed after radiation can cause delayed pnuemonitis

58
Q

Crypotegenic organising pneumonia

A

Acute, migratory infiltrates preceded by a flu-like illness for 6-8 weeks. Non-responsive to antibiotics and treated with steroids.

59
Q

Acute interstitial pneumonia

A

Mimics ARDS without the risk factors

60
Q

Idiopathic pulmonary fibrosis

A

> 50 years
Radiological findings of usual interstitial pneumonia
Diagnosis of exclusion
Associated with Telomeropathy syndrome ; Short telomeres found in 20-25% of patients
Rx anti-fibrotics; slows progression but not mortality

61
Q

Non-specific pulmonary fibrosis

A
  • Young population
  • Bilateral lower lobe reticular changes
  • ground glass without Honeycombing
  • Commonly associated with autoimmune disease

Types;
- Cellular
Worse prognosis and poor response to treatment
- Fibrotic
Better prognosis and response to treatment

62
Q

Lights criteria

A

For exudative effusion
Fluid Protein: Serum protein > 0.5
Fluid LDH: Serum LDH > 0.6
Fluid LDH > 2/3 normal serum LDH

63
Q

Types Pulmonary HTN

A